Literature DB >> 25614860

QT Dispersion after Thrombolytic Therapy.

Saeed Oni Heris1, Behzad Rahimi2, Gholamreza Faridaalaee3, Mojgan Hajahmadi2, Hojjat Sayyadi4, Bahman Naghipour5.   

Abstract

BACKGROUND: QT dispersion (QTd) is equal to longer QTc minus shorter QTc measured by 12-lead electrocardiogram (ECG). QTd reflects inhomogeneity in repolarization of ventricular myocardium and because of easy and fast measurement of QTd, it can be used to predict high-risk patients for dysrhythmia after Acute Myocardial Infarction (AMI).
OBJECTIVES: This study aimed to assess the effect of thrombolytic therapy on QTd before and 1 hour and 4 days after beginning of thrombolytic therapy. PATIENTS AND METHODS: The patients with chest pain and ST Elevated Myocardial Infarction (STEMI) that underwent thrombolytic therapy were enrolled into this study. Streptokinase was the thrombolytic agent in all the patients. Standard 12-lead (ECG) was evaluated before beginning of thrombolytic therapy (QTd 1) and 1 hour (QTd2) and 4 days (QTd3) after thrombolytic therapy. First, ECG was magnified × 10 for exact calculation of QT and QTd. After all, the variables were compared using one-way analysis of variance (ANOVA). Besides, P ≤ 0.05 was considered as statistically significant.
RESULTS: This study was conducted on 160 patients. The results revealed no significant differences among QTd 1, QTd 2, and QTd 3 (P > 0.05). At inferior AMI, however, a significant difference was observed among QTd1, QTd2, and QTd3 (P = 0.031).
CONCLUSIONS: Thrombolytic therapy had no significant effects on QTd. Thus, thrombolytic therapy does not increase the risk of arrhythmia.

Entities:  

Keywords:  Electrocardiography; Myocardial Infarction; QT; Streptokinase; Thrombolysis

Year:  2014        PMID: 25614860      PMCID: PMC4302504     

Source DB:  PubMed          Journal:  Int Cardiovasc Res J        ISSN: 2251-9130


1. Background

QT interval is defined as the distance from the onset of QRS complex to the end of T wave on electrocardiogram. QT dispersion (QTd) is equal to longer QTc minus shorter QTc measured by 12-lead Electrocardiogram (ECG). QTd reflects inhomogeneity in myocardial and ventricular repolarization (1, 2). Because of easy and fast measurement of QTd, it can be used to predict high-risk patients for dysrhythmia after Acute Myocardial Infarction (AMI) (3). QTd is 30 - 60 milliseconds (ms) in healthy patients, but increases to 60 - 80 ms in patients with Coronary Artery Disease (CAD) (4). QTc dispersion > 60 ms has independent predictive value for the severity of CAD (5). In addition, QTd increases after the acute phase of AMI (6). Increased QTd can cause ventricular arrhythmia, such as torsade de pointes (7-10). Reperfusion therapy is the cornerstone of treatment for AMI. Reperfusion therapy is done with thrombolytic drugs and Percutaneous Coronary Intervention (PCI). PCI can decrease QTd (11). PCI, within 90 minutes after the beginning of MI, is the choice of reperfusion therapy. Unfortunately, there is no PCI facility at many hospitals, especially in developing countries. Thus, thrombolytic therapy is done for treatment of AMI in such hospitals. In some patients, ventricular arrhythmias occur during or after reperfusion therapy.

2. Objectives

Hence, the present study aims to assess the effect of thrombolytic therapy on QTd as a predictive value for ventricular arrhythmias.

3. Patients and Methods

This descriptive-analytical (observational) study was conducted on all the patients with acute ST Elevated Myocardial Infarction (STEMI) and chest pain who underwent thrombolytic therapy in Seyedoshohada hospital, Urmia, Iran. Overall, 183 patients were enrolled into the study. Streptokinase was the thrombolytic agent in all the patients. The exclusion criteria of the study were electrolyte disturbances, conduction disturbances, Atrial Fibrillation (AF), and chronic use of drugs, such as digital drugs, antidepressants, and antipsychotics. Thus, 23 patients were excluded from the study due to electrolyte disturbances (hyponatremia) (N = 2), chronic use of digoxin (N = 5), AF (N = 5), conduction disturbances (N = 10; 4, 5, and 1 patients had left bundle branch block, right bundle branch block, and complete heart block, respectively), and death (N = 1). After all, 160 patients were recruited into this study. Standard 12-lead ECG (Speed: 25 millimeter per second) was evaluated before thrombolytic therapy (QTd 1), one hour after therapy (QTd2), and four days after therapy (QTd QTd 3). First, the ECG was magnified × 10 to clarify ECG paper for precise measurements. Longer and shorter QTs of 12-lead ECG were measured manually, and QTd was measured using the following formula: longer QT minus shorter QT. Then, corrected QTd was calculated through Bazett’s formula (QTd corrected = QTd / √RR) (Bazett’s formula: Corrected QT = QTc = QT / √ RR). All the statistical analyses were performed using the SPSS statistical software (v. 19). Normally distributed continuous variables were expressed as mean ± standard deviation. Abnormally distributed variables were expressed as median. Non-continuous data were expressed as number of events and percentage. Student T-test and one–way analysis of variance (ANOVA) were used to compare normally distributed continuous variables. P ≤ 0.05 was considered as statistically significant.

4. Results

This study was conducted on 160 patients. In all the patients, reversing ST elevation of ECG showed successful reperfusion therapy, but no angiographic data were available to exactly determine the success of reperfusion therapy and this defect of data was one of the study limitations. In this study, 122 patients were male and 38 ones were female. In addition, 105 and 55 patients were above and below 65 years old, respectively. Table 1 summarizes the patients’ characteristics and demographic data.
Table 1.

The Patients' Characteristics and Demographic Data

FrequencyPercent
Male 12276.25
Female 3823.75
Age < 65 5534.375
Age ≥ 65 10565.625
Anterior MI 8452.5
Inferior MI 5433.75
Lateral MI 74.375
Extensive or mixed MI 159.375
With previous hypertension 5333.125
Without previous hypertension 10766.875
With previous DM 2415
Without previous DM 13685
Smoker 7245
Non-smoker 8855
Total 160100

Abbreviations: MI, myocardial infarction; DM, diabetic mellitus

Abbreviations: MI, myocardial infarction; DM, diabetic mellitus QTd interval, mean QTd, and standard deviation over time have been presented in Table 2. Accordingly, although QTd 2 was lower than QTd 1, the difference was not statistically significant (P = 0.831).
Table 2.

Over Time QTd Interval

QTd 1QTd 2QTd 3
Minimum QTd 000
Maximum QTd 204.96 ms194.03 ms244.95 ms
Mean QTd 76.15 ms70.93 ms76.69 ms
SD 35.50227.9847.81

Abbreviations: QTd 1, QTd at first ECG; QTd 2, QTd 1 hour after beginning of reperfusion therapy; QTd 3, QTd 4, days after beginning of reperfusion therapy; SD, standard deviation; ms, millisecond

Abbreviations: QTd 1, QTd at first ECG; QTd 2, QTd 1 hour after beginning of reperfusion therapy; QTd 3, QTd 4, days after beginning of reperfusion therapy; SD, standard deviation; ms, millisecond In this study, error bars graphs were drawn to indicate the estimated error in a measurement (Figure 1). In this figure, the Y-axis represents the column mean and the upper and lower errors represent the two columns' upper error and lower error, respectively.
Figure 1.

Error Bar Variation of Mean QTd

Moreover, over time QTd variation based on sex, age, site of infarction, previous smoking, hypertension, and diabetes mellitus has been shown in Table 3. As the table depicts, no significant differences were found among QTd 1, QTd 2, and QTd 3 (P > 0.05). At inferior AMI, however, a significant difference was observed among QTd1, QTd2, and QTd3 (P = 0.031). Over time QTd mean variations based on the site of infarction have been presented in Figure 2.
Table 3.

QTd Variations Based on Sex, Age, Site of Infarction, Previous Smoking, Hypertension, and Diabetes Mellitus

QTd1QTd2QTd3P value
Sex
Male 79.94 ± 37.6868.49 ± 3987.56 ± 50.060.068
Female 67.83 ± 27.0573.74 ± 33.0062.05 ± 36.040.120
With previous HTN 76.86 ± 35.1473.71 ± 48.1674.18 ± 36.150.560
Without previous HTN 69.73 ± 32.1668.93 ± 45.7277.89 ± 37.460.028
With previous DM 72.37 ± 39.1774.18 ± 42.1584.86 ± 32.110.780
Without previous DM 73.92 ± 33.6568.81 ± 25.2968.14 ± 39.410.451
With previous smoking 74.78 ± 32.1767.90 ± 40.1479.26 ± 28.250.348
Without previous smoking 71.86 ± 37.1474.66 ± 39.3673.80 ± 29.150.751
Age < 65 68.11 ± 15.4866.16 ± 11.671.11 ± 46.570.979
Age ≥ 65 78.24 ± 25.1876.28 ± 45.679.72 ± 52.540.852
Anterior AMI 79.91 ± 25.3775.14 ± 3288.11 ± 470.063
Inferior AMI 69.27 ± 3078.22 ± 4166.86 ± 340.031
Lateral AMI 62.75 ± 2860.11 ± 4178.86 ± 370.056
Mixed or extensive AMI 81.14 ± 2569.26 ± 4078.45 ± 320.089

Abbreviations: DM, Diabetes mellitus; HTN, Hypertension; AMI, Acute myocardial infarction

Figure 2.

QTd Mean Variation over Time Based on the Site of Infarction

Abbreviations: DM, Diabetes mellitus; HTN, Hypertension; AMI, Acute myocardial infarction

5. Discussion

This study was performed on 160 patients with AMI. Based on the study results, although QTd decreased during thrombolytic therapy, thrombolytic therapy had no significant effects on QTd3 (QTd after 4 days). Thus, the risk of arrhythmia did not increase 4 days after thrombolytic therapy. Similar to our study, Lörincz et al. assessed the effect of intravenous streptokinase on QT and JT dispersions. They reported that QTd increased at early hours after infarction and thrombolytic therapy, but decreased 8 ± 2 hours after thrombolytic therapy (12). Moreover, Snikiforos et al. studied 60 patients with AMI to assess the effect of reperfusion therapy [streptokinase or r-TPA and primary Percutaneous Transdermal Coronary Angioplasty (PTCA)] on QTd. They concluded that after AMI, successful thrombolysis was associated with a significant decrease in QTd on the standard 12-lead ECG (13). Furthermore, Mohammad et al. evaluated the effect of PCI on QTd in 96 patients with stable angina in 2010 and demonstrated that PCI decreased QTd (14). Karagounis et al. also conducted a study on 207 patients who underwent thrombolytic therapy with alteplase or anistreplase. Their findings indicated that after AMI, successful thrombolysis was associated with lower QTd (15). Chi-Cheng Lai et al. established that although shortened QTd showed successful reperfusion therapy, the patients with shortened QTd had significantly higher incidence of in-hospital cardiac deaths after receiving PCI (16). However, Nirav J. Mehta et al. studied the effect of thrombolytic therapy on QTd in 72 patients with AMI. They revealed that QTd did not change early after thrombolytic therapy (17). Moreover, Fukushima et al. evaluated the effect of successful recanalization on QTd in AMI patients and disclosed that successful recanalization significantly decreased QTd (18). In conclusion, thrombolytic therapy had no significant effects on QTd over time. Thus, thrombolytic therapy does not increase the risk of arrhythmia over time.
  16 in total

1.  Effect of thrombolytic therapy on QT dispersion in elderly versus younger patients with acute myocardial infarction.

Authors:  Nirav J Mehta; Ijaz A Khan; Rajal N Mehta; Bienvenido Burgonio; Gaurav Lakhanpal
Journal:  Am J Ther       Date:  2003 Jan-Feb       Impact factor: 2.688

2.  Impact of myocardial reperfusion status on QT dispersion after successful recanalization of the infarct-related artery in acute myocardial infarction.

Authors:  Noritoshi Fukushima; Yukio Tsurumi; Kentaro Jujo; Keiko Fukushima; Haruki Sekiguchi; Atsushi Honda; Dai Yumino; Masatoshi Kawana; Nobuhisa Hagiwara
Journal:  J Interv Cardiol       Date:  2014-01-23       Impact factor: 2.279

3.  QT interval dispersion and its clinical utility.

Authors:  J Kautzner; M Malik
Journal:  Pacing Clin Electrophysiol       Date:  1997-10       Impact factor: 1.976

4.  QT interval prolongation as predictor of sudden death in patients with myocardial infarction.

Authors:  P J Schwartz; S Wolf
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

5.  Effect of percutaneous coronary intervention of nonacute total coronary artery occlusions on QT dispersion.

Authors:  David M Goodhart; Jaroslav Hubacek; Todd J Anderson; Hank Duff; Gerald Barbeau; John Ducas; Ronald G Carere; Charles Lazzam; Vladimir Dzavik; Christopher E Buller; Mouhieddin Traboulsi
Journal:  Am Heart J       Date:  2006-02       Impact factor: 4.749

Review 6.  [Heterogeneities of ventricular repolarization and vulnerability to arrhythmia. How to detect them with noninvasive methods?].

Authors:  L De Ambroggi
Journal:  Cardiologia       Date:  1999-04

7.  The Relation Between Early Ventricular Tachycardia and QT Dispersion in Patients with Acute Myocardial Infarction Treated with Thrombolytic Therapy.

Authors:  Rasim Enar; Seçkin Pehlivano&gbreve;lu; Alev Arat; Ahmet Yildiz; Nuran Yazicio&gbreve;lu
Journal:  Int J Angiol       Date:  2001-01

8.  QT dispersion and early arrhythmic risk in acute myocardial infarction.

Authors:  Dnyaneshwar V Mulay; Syed M Quadri
Journal:  Indian Heart J       Date:  2004 Nov-Dec

9.  Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.

Authors:  J T Hii; D G Wyse; A M Gillis; H J Duff; M A Solylo; L B Mitchell
Journal:  Circulation       Date:  1992-11       Impact factor: 29.690

10.  QT Dispersion: Does It Change after Percutaneous Coronary Intervention?

Authors:  Mohammad Alasti; Mohammad Hassan Adel; Ekhlas Torfi; Mohammad Noorizadeh; Sara Bahadoram; Mahsa Asadi Moghaddam; Mohammad Bahadoram; Bita Omidvar; Mohammad Hossein Jadbabaei
Journal:  J Tehran Heart Cent       Date:  2011-02-28
View more
  1 in total

1.  Comparison of QT dispersion in patients with ST elevation acute myocardial infarction (STEMI) before and after treatment by streptokinase versus primary percutaneous coronary intervention (PCI).

Authors:  Abbas Valizadeh; Sahar Soltanabadi; Saeed Koushafar; Maryam Rezaee; Reza Jahankhah
Journal:  BMC Cardiovasc Disord       Date:  2020-11-23       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.